Meiragtx Holdings Plc (MGTX) Stock Price & Analysis
Meiragtx Holdings Plc (MGTX) fell 2.73% to USD 11.77 as of July 25, 2026 at 06:50 UTC, according to Nexqual real-time market data.
MGTX last closed at USD 12.1; the session ranged USD 11.69–12.33 on volume of 473,678 shares. Market capitalization is $1.09B, with a 52-week range of USD 6.62–15.35 (NMS). Source: Nexqual, July 25, 2026 at 06:50 UTC.
Key Statistics (as of July 25, 2026 at 06:50 UTC)
| Price | USD 11.77 |
|---|---|
| Change | ▼ 2.73% (down) |
| Previous Close | USD 12.1 |
| Open | USD 12.3 |
| Day Range | USD 11.69 – 12.33 |
| 52-Week Range | USD 6.62 – 15.35 |
| Volume | 473,678 shares |
| Market Cap | $1.09B |
| Exchange | NMS |
Technical Analysis (MGTX)
Nexqual's technical model rates MGTX "BUY" based on 4 bullish and 2 bearish signals across 125 daily candles, as of July 25, 2026 at 06:50 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 49.14 (neutral) |
| vs SMA50 | Above (USD 11.11) |
| MACD | 0.23 (positive) |
Analyst Ratings (MGTX)
Wall Street analysts rate MGTX "Strong Buy" based on 8 analysts, with a mean price target of USD 28.38 (range USD 19–50), per Nexqual as of July 25, 2026 at 06:50 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 8 |
| Mean Target | USD 28.38 |
| High Target | USD 50 |
| Low Target | USD 19 |
| Buy / Hold / Sell | 8 / 0 / 0 |
Earnings (MGTX)
| Next Earnings Date | 2026-08-13 |
|---|---|
| EPS Estimate | USD -0.25 |
| Revenue Estimate | $21.34M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.57 vs est -0.45 ▼ miss |
| 2025-12-31 | USD 0.19 vs est -0.62 ▲ beat |
| 2025-09-30 | USD -0.62 vs est -0.49 ▼ miss |
| 2025-06-30 | USD -0.48 vs est -0.47 ▼ miss |
Source: Nexqual, July 25, 2026 at 06:50 UTC.
Financials & Fundamentals (MGTX)
| Total Revenue | $79.76M |
|---|---|
| Revenue Growth (YoY) | -84.80% |
| Gross Margin | +95.41% |
| Operating Margin | -13930.72% |
| Profit Margin | -151.12% |
| Current Ratio | 0.55 |
| Total Cash | $71.54M |
| Total Debt | $87.53M |
| Free Cash Flow | $45.02M |
Source: Nexqual, July 25, 2026 at 06:50 UTC.
Financial Health Score (MGTX)
Nexqual rates Meiragtx Holdings Plc's overall financial health "Mixed" across five dimensions, as of July 25, 2026 at 06:50 UTC.
| Growth | Strong — Revenue +145% YoY (annual) |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Mixed — $72M cash vs $88M debt |
| Cash Flow | Strong — FCF $45M, 55% margin |
| Efficiency | Mixed — No data |
Ownership (MGTX)
| Insider Ownership | +17.06% |
|---|---|
| Institutional Ownership | +61.64% |
| Shares Outstanding | 92.61M |
| Float | 52.35M |
| Short % of Float | +6.45% |
Source: Nexqual, July 25, 2026 at 06:50 UTC.
Leadership (MGTX)
Meiragtx Holdings Plc is led by Alexandria Forbes (age 60), CEO, President & Director, per Nexqual as of July 25, 2026 at 06:50 UTC.
| CEO, President & Director | Alexandria Forbes (age 60) |
|---|---|
| COO & CFO | Richard Brian Giroux B.A. (age 51) |
| Chief Scientific Officer of Ophthalmology | Stuart Naylor (age 62) |
| Senior Vice President of Global Integration | Christine Elise Sheehy (age 57) |
| Senior Vice President of Risk & Internal Controls | Tim Randall |
Major Backers & Investors (MGTX)
Notable institutional backers of Meiragtx Holdings Plc include Sanofi, Perceptive Advisors Llc, Rubric Capital Management LP, according to Nexqual as of July 25, 2026 at 06:50 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Sanofi | 13.17% |
| Perceptive Advisors Llc | 11.15% |
| Rubric Capital Management LP | 7.56% |
| Johnson & Johnson | 7.17% |
| Adage Capital Partners GP L.L.C. | 4.32% |
| Millennium Management | 3.74% |
| Prosight Management, Lp | 2.84% |
| 683 Capital Management LLC | 2.65% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 5.68% |
Source: Nexqual, July 25, 2026 at 06:50 UTC.
From Meiragtx Holdings Plc's Latest SEC 10-K Filing (filed 2026-03-30)
Key Strengths & Strategy (as disclosed to the SEC)
- MeiraGTx Holdings plc, a clinical-stage genetic medicines company, focusing on developing treatments for patients with serious diseases.
- The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases; neurodegenerative diseases; and xerostomia.
- It is also develops AAV-AQP1 for radiation-induced grade 2/3 radiation-induced xerostomia, as well as for Sjogren's syndrome; AAV-GAD in Phase 2 trial for Parkinson's disease; AAV-RPE65 in Phase 2 trial for RPE65-associated retinal dystrophy; and AAV-CNGB3 and AAV-CNGA3, which are both in Phase ½ clinical trial for achromatopsia, as well as offers AAV-AIPL1 for Leber congenital amaurosis (LCA) 4.
- In addition, the company's products under preclinical development include AAV-RDH12 for retinol dehydrogenase 12 mutation-associated retinal dystrophy; AAV-BBS10 for Bardet-Biedl syndrome (BBS) due to BBS10 mutations; AAV-RetGC for LCA type 1; and AAV-UPF1 for amyotrophic lateral sclerosis, as well as programs for Alzheimer's disease, and wet and dry neovascular age related macular degeneration.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| RGNX | REGENXBIO Inc. | USD 9.73 | ▼ 4.61% |
| STOK | Stoke Therapeutics, Inc. | USD 29.3 | ▲ 1.17% |
| CRNX | Crinetics Pharmaceuticals, Inc. | USD 83.73 | ▲ 0.01% |
| VYGR | Voyager Therapeutics, Inc. | USD 3.1 | ▲ 0% |
| REPL | Replimune Group, Inc. | USD 9.7 | ▼ 9.77% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 06:50 UTC. This page is informational and not investment advice.